Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Lundbeck

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Lundbeck's 2013 CNS (central nervous system) sales performance.

Teva’s weak pipeline hit by Tourette’s drug trial failure

Teva’s weak pipeline hit by Tourette’s drug trial failure

There are a few other candidates in development however, including Lundbeck’s mid-stage drug  ABX-1431, an MGLL inhibitor acquired along with Abide Therapeutics last year, Therapix’ tetrahydrocannabidiol-based

Allergan gets FDA nod for first oral CGRP drug for migraine

Allergan gets FDA nod for first oral CGRP drug for migraine eptinezumab from Alder Biopharma – now  owned by Lundbeck – in late-stage development.

The mission matters

The mission matters economics. As Deborah Dunsire, CEO of Lundbeck, put it, our industry demands a very high concentration of intellectual capital across a very wide range of disciplines.

Low-dose LSD looks safe for Alzheimer’s patients, but will it work?

Low-dose LSD looks safe for Alzheimer’s patients, but will it work? Other treatments targeting serotonin pathways in Alzheimer’s haven’t proved to be successful – such as Lundbeck and Otsuka’s 5-HT.

Darwinian leadership in the life sciences industry

Darwinian leadership in the life sciences industry Or, to use the crisper, to-the-point description given by Lundbeck’s Deborah Dunsire, to be a world-class life sciences company requires a very high concentration of intellectual capital

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics